Outlook Therapeutics (OTLK) Share-based Compensation (2015 - 2026)
Outlook Therapeutics (OTLK) posted quarterly Share-based Compensation of $3.3 million for Q1 2026, up 91.68% year-over-year from $1.7 million in Q1 2025, and up 270.6% quarter-over-quarter from $881150.0 in Q4 2025.
Outlook Therapeutics (OTLK) Share-based Compensation (2015 - 2026) Analysis & Trends
Outlook Therapeutics (OTLK) has reported Share-based Compensation for 12 consecutive years, with $3.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Share-based Compensation rose 91.68% year-over-year to $3.3 million; the TTM figure through Mar 2026 stood at $3.3 million (down 60.07% YoY), while the FY2025 annual figure was $8.9 million, up 18.51% from the prior year.
- Share-based Compensation improved to $3.3 million in Q1 2026 per OTLK's latest filing, from $881150.0 in the prior quarter.
- Across five years, Share-based Compensation topped out at $3.8 million in Q1 2022 and bottomed at $881150.0 in Q4 2025.
- Historically, Share-based Compensation has averaged $1.8 million across 5 years, with a median of $1.4 million in 2022.
- Annual changes were most pronounced in 2022 — Share-based Compensation jumped 233.07% — and 2025, when it sank 76.01%.
- Outlook Therapeutics' Share-based Compensation stood at $1.4 million in 2022, then slipped by 8.6% to $1.3 million in 2023, then soared by 188.57% to $3.7 million in 2024, then tumbled by 76.01% to $881150.0 in 2025, then surged by 270.6% to $3.3 million in 2026.
- Business Quant data shows OTLK's Share-based Compensation at $3.3 million in Q1 2026, $881150.0 in Q4 2025, and $1.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Outlook Therapeutics | 88.50 Mn | 77.26 Mn | -8,265.00 | 791,671.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.27 Mn |
| Mar 31, 2026 | 3.27 Mn |
| Dec 31, 2025 | 881,150.00 |
| Dec 31, 2025 | 881,150.00 |
| Sep 30, 2025 | 1.82 Mn |
| Sep 30, 2025 | 1.82 Mn |
| Jun 30, 2025 | 1.67 Mn |
| Jun 30, 2025 | 1.67 Mn |
| Mar 31, 2025 | 1.70 Mn |
| Mar 31, 2025 | 1.70 Mn |
| Dec 31, 2024 | 3.67 Mn |
| Dec 31, 2024 | 3.67 Mn |
| Sep 30, 2024 | 1.41 Mn |
| Sep 30, 2024 | 1.41 Mn |
| Jun 30, 2024 | 1.40 Mn |
| Jun 30, 2024 | 1.40 Mn |
| Mar 31, 2024 | 1.31 Mn |
| Mar 31, 2024 | 1.31 Mn |
| Dec 31, 2023 | 1.27 Mn |
| Dec 31, 2023 | 1.27 Mn |